SITC 2021: Highlight Therapeutics' BO-112 boosts checkpoint response rate in phase II | 2021-11-12 | BioWorld
Marisol Quintero - CEO at Highlight Therapeutics | The Org
Our Instructors — Highlight Therapeutics
Highlight Therapeutics SL | LinkedIn
Highlight Therapeutics
Highlight Therapeutics and Pivotal work together on Melanoma therapy and launch a Phase IIa trial to examine BO-112 efficacy and safety - Pivotal
LabCentral (@LabCentral) / X
BIONCOTECH
Highlight Therapeutics SL (@Highlight_HLT) / X
Our Instructors — Highlight Therapeutics
Highlight Therapeutics: on a mission to extend benefits of immuno-oncology drugs
Our Instructors — Highlight Therapeutics
Classes — Highlight Therapeutics
Elena Caballero Castellote on LinkedIn: HIGHLIGHT THERAPEUTICS Phase 2 results Final
Elena Caballero Castellote on LinkedIn: HIGHLIGHT THERAPEUTICS Phase 2 results Final
IAM questionnaire linked to a Highlight from e-Therapeutics+® | Download Scientific Diagram
Quibim works with Highlight Therapeutics to improve immunotherapy in melanoma with AI | MobiHealthNews
Marisol Quintero email address & phone number | Highlight Therapeutics SL CEO contact information - RocketReach
Highlight Therapeutics & Pivotal advance into a phase IIa to examine gastro-intestinal cancer therapy - Pivotal
Dr. María D. Mayán on X: "Innovation from the benchside What a round table with @LauraSoucek @VHIO CEO @peptomyc Marisol Quintero, CEO de Highlight Therapeutics, @mfuentefreire CEO @DIVERSATechnlgs & Eduard Batlle PI
AIChE Journal Highlight: Sustained Ocular Delivery of Anti-Inflammatory Therapeutics | AIChE
Zuzana Jirakova Trnkova - Highlight Therapeutics SL | LinkedIn
Highlight Therapeutics & Pivotal advance into a phase IIa to examine gastro-intestinal cancer therapy - Pivotal
Highlight Therapeutics - Crunchbase Company Profile & Funding
